---
figid: PMC8021759__jitc-2020-002086f01
figlink: pmc/articles/PMC8021759/figure/F1/
number: F1
caption: Methods to circumvent antiviral immunity. Oncolytic viruses (OVs) exert their
  effect by infecting the cancer cells, replicating, and inducing oncolysis. Iimmunogenic
  cell death of the tumor subsequently activates anti-viral and anti-tumor T cells.
  However, viral activity is limited by the humoral, innate and adaptive cellular
  immune components of the host. Several approaches aim to counteract each arm of
  the immune system to protect the viruses and maximize tumor regression. OVs can
  be shielded from the humoral immune responses of B cells and the complement pathway
  through encapsulation OVs in protective coatings and cellular carriers, genetic
  modification of the viral capsid to reduce expression of common viral epitopes,
  and administration of bispecific engagers that can bind neutralizing antibodies
  and tumors cells on different ends. To confer OVs stealth characteristic, the innate
  immunity can be tamed through the inhibition of the anti-viral interferon (IFN)
  pathway, the natural killer cells and antigen presentation. T cell immunodominance
  from viral antigens can be overcome through nanoparticle-enveloped viral antigens
  and tolerogenic dendritic cells. ISG, interferon-stimulated gene; ISRE, interferon-stimulated
  response element; MHC, major histocompatibility complex; NK, natural killer; TAP,
  transporter associated with antigen processing.
pmcid: PMC8021759
papertitle: Current strategies to circumvent the antiviral immunity to optimize cancer
  virotherapy.
reftext: Dong Ho Shin, et al. J Immunother Cancer. 2021;9(4):e002086.
pmc_ranked_result_index: '42632'
pathway_score: 0.9129787
filename: jitc-2020-002086f01.jpg
figtitle: Methods to circumvent antiviral immunity
year: '2021'
organisms:
- Mus musculus
- Vaccinia virus
- Human alphaherpesvirus 1
- Maraba virus
- Adenoviridae
- Reovirus sp.
- Semliki Forest virus
- Sindbis virus
- Measles morbillivirus
- Vesicular stomatitis virus
- Bikinia letestui
- Adeno-associated virus
- prion
- Candida dubliniensis
- recombinant polioviruses
- Homo sapiens
- Alphavirus M1
- Bos taurus
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8021759__jitc-2020-002086f01.html
  '@type': Dataset
  description: Methods to circumvent antiviral immunity. Oncolytic viruses (OVs) exert
    their effect by infecting the cancer cells, replicating, and inducing oncolysis.
    Iimmunogenic cell death of the tumor subsequently activates anti-viral and anti-tumor
    T cells. However, viral activity is limited by the humoral, innate and adaptive
    cellular immune components of the host. Several approaches aim to counteract each
    arm of the immune system to protect the viruses and maximize tumor regression.
    OVs can be shielded from the humoral immune responses of B cells and the complement
    pathway through encapsulation OVs in protective coatings and cellular carriers,
    genetic modification of the viral capsid to reduce expression of common viral
    epitopes, and administration of bispecific engagers that can bind neutralizing
    antibodies and tumors cells on different ends. To confer OVs stealth characteristic,
    the innate immunity can be tamed through the inhibition of the anti-viral interferon
    (IFN) pathway, the natural killer cells and antigen presentation. T cell immunodominance
    from viral antigens can be overcome through nanoparticle-enveloped viral antigens
    and tolerogenic dendritic cells. ISG, interferon-stimulated gene; ISRE, interferon-stimulated
    response element; MHC, major histocompatibility complex; NK, natural killer; TAP,
    transporter associated with antigen processing.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CD8A
  - CD8B
  - CD4
  - CLU
  - AKR1C4
  - C2
  - IFNA1
  - KLRG1
  - IFNA2
  - IFNA4
  - IFNA5
  - IFNA7
  - IFNA8
  - IFNA17
  - IFNA6
  - IFNA10
  - IFNA13
  - IFNA14
  - IFNA16
  - IFNA21
  - JAK3
  - JAK2
  - CDH1
  - TAP1
  - TAP2
  - ABCB9
  - IRF9
  - STAT2
genes:
- word: CD8
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8A
  entrez: '925'
- word: CD8
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8B
  entrez: '926'
- word: CD4
  symbol: CD4
  source: hgnc_symbol
  hgnc_symbol: CD4
  entrez: '920'
- word: CD8
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8A
  entrez: '925'
- word: CD8
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8B
  entrez: '926'
- word: cll
  symbol: CLI
  source: hgnc_prev_symbol
  hgnc_symbol: CLU
  entrez: '1191'
- word: cll
  symbol: C11
  source: hgnc_alias_symbol
  hgnc_symbol: AKR1C4
  entrez: '1109'
- word: cll
  symbol: C2
  source: hgnc_symbol
  hgnc_symbol: C2
  entrez: '717'
- word: IFN
  symbol: IFN
  source: hgnc_alias_symbol
  hgnc_symbol: IFNA1
  entrez: '3439'
- word: KLRG1
  symbol: KLRG1
  source: hgnc_symbol
  hgnc_symbol: KLRG1
  entrez: '10219'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA1
  entrez: '3439'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA2
  entrez: '3440'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA4
  entrez: '3441'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA5
  entrez: '3442'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA7
  entrez: '3444'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA8
  entrez: '3445'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA17
  entrez: '3451'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA6
  entrez: '3443'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA10
  entrez: '3446'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA13
  entrez: '3447'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA14
  entrez: '3448'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA16
  entrez: '3449'
- word: IFNa
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA21
  entrez: '3452'
- word: IFN
  symbol: IFN
  source: hgnc_alias_symbol
  hgnc_symbol: IFNA1
  entrez: '3439'
- word: JAKI
  symbol: JAKL
  source: hgnc_alias_symbol
  hgnc_symbol: JAK3
  entrez: '3718'
- word: JAK2
  symbol: JAK2
  source: hgnc_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: E-cadherin
  symbol: CDH1
  source: hgnc_symbol
  hgnc_symbol: CDH1
  entrez: '999'
- word: IFN
  symbol: IFN
  source: hgnc_alias_symbol
  hgnc_symbol: IFNA1
  entrez: '3439'
- word: ТАР
  symbol: TAP
  source: bioentities_symbol
  hgnc_symbol: TAP1
  entrez: '6890'
- word: ТАР
  symbol: TAP
  source: bioentities_symbol
  hgnc_symbol: TAP2
  entrez: '6891'
- word: ТАР
  symbol: TAP
  source: bioentities_symbol
  hgnc_symbol: ABCB9
  entrez: '23457'
- word: IRF9
  symbol: IRF9
  source: hgnc_symbol
  hgnc_symbol: IRF9
  entrez: '10379'
- word: STAT2
  symbol: STAT2
  source: hgnc_symbol
  hgnc_symbol: STAT2
  entrez: '6773'
chemicals: []
diseases: []
figid_alias: PMC8021759__F1
redirect_from: /figures/PMC8021759__F1
figtype: Figure
---
